Denis Schertenleib
Partner
Lawyer registered at the Paris Bar
Solicitor of England & Wales
Ph.D. in Molecular Biology (King's College London)
Associate of Royal College of Science of London
Denis is the founder of Schertenleib Avocats.
Having run more than fifty patent cases, he has an established reputation in this area.
With a Bachelor of science in physics and a Ph.D. in molecular neurobiology, Denis's scientific knowledge enables him to understand the technical elements of a case and to provide tailored legal solutions across a variety of technical fields.
Denis’s practice is focused on complex cross-border disputes, principally in the area of life sciences but also in other technical fields such as chemistry, mechanics, telecommunications, and physics.
Denis’s experience includes cases before French, English, and European courts and tribunals, as well as arbitral tribunals, across the lifecycle of proceedings, from preliminary injunction through to final hearing on the merits.
Denis also has extensive knowledge regarding technology transfers, European competition law applied to intellectual property, and regulatory law in the pharmaceutical field.
Prior to establishing Schertenleib Avocats, Denis worked at an international law firm in London and was also a partner at a specialised intellectual property law firm in Paris for several years.
Denis is fluent in French and English.
Education
Ph.D. in Molecular Neurobiology, King's College London
Bachelor of Science in Physics, Imperial College London, 1st class honours
Affiliation
AIPPI, AAPI
What others say
“ He is rare for a French IP lawyer – he has a scientific background and trained as a solicitor at a UK firm before returning to Paris to advise at the French Patent Bar. As a result, he has great technical understanding of the most complex biotechnology and other high-technology patents and also a very international outlook. IAM Patent 2023
"Denis Schertenleib is very experienced both technically in the science of patents and the workings of the patent laws and systems." Legal500 2022
"Dual-qualified in France and the UK, the "very knowledgeable" Denis Schertenleib impresses with his expertise in domestic and multi-jurisdictional patent infringement, revocation and nullity litigations." Chambers 2022
Significant public cases
-
Represented a generic company in the defence of a patent infringement action relating to a urea aryl compound used in the treatment of human cancers;
-
Represented a generic company in an action for invalidation of a patent relating to the treatment of thromboembolic disorders;
-
Represented a generic company in an infringement action brought by an originator company on the basis of a SPC combining sitagliptin with metformin for the treatment of diabetes;
-
Represented a major player in aesthetic medicine in a dispute concerning know-how (claims of more than 150 million euros) and two patents relating to a process for manufacturing hyaluronic acid fillers;
-
Represented a company specialising in the manufacture of electronic products and mobile phones against a telecommunications company in a contractual action aimed at obtaining a FRAND licence;
-
Represented a generic laboratory in defence of patent infringement litigation relating to a cytostatic anti-cancer agent;
-
Represented a laboratory manufacturing diagnostic medical devices in an arbitration;
-
Represented a generic company in a patent invalidity action relating to analogues of gaba and L-glutamic acid for the treatment of central nervous system diseases;
-
Represented a generic company in a patent infringement action relating to zidovudine combinations for the treatment of HIV;
-
Represented an originator company in a patent infringement action relating to a monoclonal antibody used in the treatment of diabetes;
-
Represented an innovator company against an originator company in an action for invalidation of two patents relating to the prevention and treatment of amyloidogenic diseases;
-
Represented a generic laboratory in an infringement action brought by an originator laboratory on a patent relating to a molecule allowing the preparation of a pharmaceutical composition to treat pain;
-
Represented a company specialising in 3D cinema technology in a patent infringement action relating to polarisation conversion systems for stereoscopic projection;
-
Represented a generic laboratory in an action for invalidation of a patent relating to a dibenzothiazepine derivative protecting a sustained release formulation and its use in the treatment of psychotic states in humans;
-
Represented a medical device company in a patent infringement action relating to a method of diagnosing sepsis;
-
Represented a generic company in an action for invalidation of an SPC relating to the combination of tenofovir disoproxil and its salts, hydrates, tautomers and solvates in combination with other therapeutic compounds in the treatment of HIV;
-
Represented a generic company in an action to invalidate an SPC for a combination of efavirenz, emtricitabine and tenofovir in the treatment of HIV;
-
Represented a laboratory manufacturing diagnostic medical devices in a civil liability action for the alleged defectiveness of its diagnostic tests for Lyme disease;
-
Represented a generic company in an action for invalidity of a SPC for the combination of ezetimibe and simvastatin;
-
Represented a generic company in a dispute before the administrative court concerning the marketing authorisation of a drug based on bendamustine hydrochloride;
-
Represented a generic company against an originator company in an action for infringement and unfair competition of three patents relating to an anti-estrogen effective in the treatment of breast cancer;
-
Represented a generic company in the defence of an action for interim injunction brought by an originator company in respect of a SPC relating to darunavir, a treatment for HIV;
-
Represented a generic company in the defence of summary proceedings and on the merits of infringement proceedings brought by an originator company on the basis of a SPC relating to a combination of ezetimibe and simvastatin in an anticholesterol treatment;
-
Represented a pharmaceutical and medical device consulting company against a French laboratory in a contractual liability action;
-
Represented a generic company in an infringement action brought by an originator company against a patent relating to the combination of pemetrexed and vitamin B12.